Knockdown of lncRNA FOXD2-AS1 Inhibits Proliferation, Migration, and Drug Resistance of Breast Cancer Cells

Nong, Qiaohong; Yu, Shaokang; Hu, Hui; Hu, Xue

doi:10.1155/2021/9674761

Cited by 9 publications

(5 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FOXD2-AS1 may promote pancreatic cancer cell invasion and migration by sponging miR-30a-3p, which upregulates COX-2 ( Ye et al, 2022 ). FOXD2-AS1 promotes breast cancer cell proliferation, invasion, migration, and drug resistance by positively regulating the PI3K/AKT signaling pathway, inhibits apoptosis, and accelerates breast cancer progression ( Nong et al, 2021 ). We discovered that no relevant literature has reported its role in ccRCC.…”

Section: Discussionmentioning

confidence: 99%

Cuproptosis-related lncRNA: Prediction of prognosis and subtype determination in clear cell renal cell carcinoma

Huili

Nie²,

Zhang³

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

Background: Clear cell renal cell carcinoma (ccRCC) is the most common type of renal cell carcinoma, accounting for approximately 70% of all RCC cases. Cuproptosis, a novel mechanism of cell death, may be a potential target for intervention in tumor development.Methods: Cuproptosis-related prognostic lncRNAs were identified by co-expression analysis and univariable Cox regression. Five lncRNA profiles were obtained by LASSO regression analysis, and a model with high accuracy was constructed to assess the prognosis of ccRCC patients based on these cuproptosis-related lncRNAs. Survival analysis and time-dependent ROC curves were performed for the α and β groups, and the results confirmed the high accuracy of the model in predicting the prognosis of ccRCC patients. Immunoassay, principal component analysis (PCA), and drug sensitivity analysis were also performed for different risk categories. Finally, we classified ccRCC patients into two different subtypes by consistent class clustering, and performed immune checkpoint activation, tumor microenvironment analysis, PCA, and drug sensitivity analysis for different subtypes.Results: We developed a prognostic model using five cuproptosis-associated lncRNAs, which was found to be highly accurate in predicting ccRCC patients’ prognosis. Immunotherapy may be more beneficial to the hyper-risk category and the C2 subtype.Conclusion: The results of this study confirm that five cuproptosis-associated lncRNAs can be used as potential prognostic markers for ccRCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Cuproptosis-related lncRNA: Prediction of prognosis and subtype determination in clear cell renal cell carcinoma

Huili

Nie²,

Zhang³

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

show abstract

“…HOTAIR was also reported to reinforce DOX resistance by promoting the phosphorylation of AKT and activating AKT/mTOR signaling pathway in BC ( Li Z. et al, 2019 ). Other lncRNAs implicated in PI3K signaling pathway and DOX resistance included FOXD2-AS1 in BC and DUXAP8 in B-cell acute lymphoblastic leukemia (B-ALL), further uncovering the central role of PI3K pathway in cancer DOX resistance ( Nong et al, 2021 ; Zhang et al, 2022 ).…”

Section: Pi3k Signaling Pathwaymentioning

confidence: 99%

Insights into the involvement of long non-coding RNAs in doxorubicin resistance of cancer

Zhang,

Hu,

Deng

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Doxorubicin is one of the most classical chemotherapeutic drugs for the treatment of cancer. However, resistance to the cytotoxic effects of doxorubicin in tumor cells remains a major obstacle. Aberrant expression of long non-coding RNAs (lncRNAs) has been associated with tumorigenesis and development via regulation of chromatin remodeling, transcription, and post-transcriptional processing. Emerging studies have also revealed that dysregulation of lncRNAs mediates the development of drug resistance through multiple molecules and pathways. In this review, we focus on the role and mechanism of lncRNAs in the progress of doxorubicin resistance in various cancers, which mainly include cellular drug transport, cell cycle disorder, anti-apoptosis, epithelial-mesenchymal transition, cancer stem cells, autophagy, tumor microenvironment, metabolic reprogramming and signaling pathways. This review is aimed to provide potential therapeutic targets for future cancer therapy, especially for the reversal of chemoresistance.

show abstract

“…FOXD2-AS1 also down regulated the p-AKT and pPI3K to inhibit the PI3K/AKT signaling pathway in BC cells. Furthermore, inhibition of FOXD2-AS1 negatively regulated the growth, aggressiveness, and migration of BC cells while induced apoptosis and chemosensitivity [ 46 ]. There was SOX21-AS1 up regulation in BC tissues that was correlated with tumor stage, grade, metastasis, and clinical outcomes.…”

Section: Introductionmentioning

confidence: 99%

Long non-coding RNAs as the critical regulators of PI3K/AKT, TGF-β, and MAPK signaling pathways during breast tumor progression

Maharati,

Moghbeli

2023

J Transl Med

View full text Add to dashboard Cite

Breast cancer (BC) as one of the most common causes of human deaths among women, is always considered one of the global health challenges. Despite various advances in diagnostic and therapeutic methods, a significant percentage of BC patients have a poor prognosis due to the lack of therapeutic response. Therefore, investigating the molecular mechanisms involved in BC progression can improve the therapeutic and diagnostic strategies in these patients. Cytokine and growth factor-dependent signaling pathways play a key role during BC progression. In addition to cytokines and growth factors, long non-coding RNAs (lncRNAs) have also important roles in regulation of such signaling pathways. Therefore, in the present review we discussed the role of lncRNAs in regulation of PI3K/AKT, MAPK, and TGF-β signaling pathways in breast tumor cells. It has been shown that lncRNAs mainly have an oncogenic role through the promotion of these signaling pathways in BC. This review can be an effective step in introducing the lncRNAs inhibition as a probable therapeutic strategy to reduce tumor growth by suppression of PI3K/AKT, MAPK, and TGF-β signaling pathways in BC patients. In addition, considering the oncogenic role and increased levels of lncRNAs expressions in majority of the breast tumors, lncRNAs can be also considered as the reliable diagnostic markers in BC patients.

show abstract

Knockdown of lncRNA FOXD2-AS1 Inhibits Proliferation, Migration, and Drug Resistance of Breast Cancer Cells

Cited by 9 publications

References 35 publications

Cuproptosis-related lncRNA: Prediction of prognosis and subtype determination in clear cell renal cell carcinoma

Cuproptosis-related lncRNA: Prediction of prognosis and subtype determination in clear cell renal cell carcinoma

Insights into the involvement of long non-coding RNAs in doxorubicin resistance of cancer

Long non-coding RNAs as the critical regulators of PI3K/AKT, TGF-β, and MAPK signaling pathways during breast tumor progression

Contact Info

Product

Resources

About